KR20040104513A - 당뇨병 및 당뇨병의 합병증과 관련된 상태를 포함한당뇨병의 치료방법 - Google Patents

당뇨병 및 당뇨병의 합병증과 관련된 상태를 포함한당뇨병의 치료방법 Download PDF

Info

Publication number
KR20040104513A
KR20040104513A KR10-2004-7014408A KR20047014408A KR20040104513A KR 20040104513 A KR20040104513 A KR 20040104513A KR 20047014408 A KR20047014408 A KR 20047014408A KR 20040104513 A KR20040104513 A KR 20040104513A
Authority
KR
South Korea
Prior art keywords
phytostanol
group
phytosterol
insulin
derivatives
Prior art date
Application number
KR10-2004-7014408A
Other languages
English (en)
Korean (ko)
Inventor
해이든 피. 프릿치하드
키쇼르 엠. 와산
타트자나 루키
Original Assignee
포비스 메디-테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포비스 메디-테크 인코포레이티드 filed Critical 포비스 메디-테크 인코포레이티드
Publication of KR20040104513A publication Critical patent/KR20040104513A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2004-7014408A 2002-03-14 2003-03-14 당뇨병 및 당뇨병의 합병증과 관련된 상태를 포함한당뇨병의 치료방법 KR20040104513A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9874502A 2002-03-14 2002-03-14
US10/098,745 2002-03-14
PCT/CA2003/000369 WO2003075931A1 (en) 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus

Publications (1)

Publication Number Publication Date
KR20040104513A true KR20040104513A (ko) 2004-12-10

Family

ID=27804294

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7014408A KR20040104513A (ko) 2002-03-14 2003-03-14 당뇨병 및 당뇨병의 합병증과 관련된 상태를 포함한당뇨병의 치료방법

Country Status (11)

Country Link
EP (1) EP1482950A1 (pt)
JP (1) JP2005528353A (pt)
KR (1) KR20040104513A (pt)
CN (1) CN1681514A (pt)
AU (1) AU2003218547B2 (pt)
BR (1) BR0308396A (pt)
CA (1) CA2478931A1 (pt)
NO (1) NO20044346L (pt)
NZ (1) NZ535200A (pt)
RU (1) RU2334518C2 (pt)
WO (1) WO2003075931A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
AU2010298733B2 (en) * 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
AU2016314373A1 (en) * 2015-09-03 2018-03-29 Natural Shield Israel 2016 Ltd Combined compositions for controlling blood sugar levels, hepatoprotection, and for prevention and treatment of related medical conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease

Also Published As

Publication number Publication date
AU2003218547B2 (en) 2007-11-01
NZ535200A (en) 2007-07-27
CA2478931A1 (en) 2003-09-18
BR0308396A (pt) 2005-01-11
RU2334518C2 (ru) 2008-09-27
AU2003218547A1 (en) 2003-09-22
NO20044346L (no) 2004-12-09
RU2004130463A (ru) 2005-04-10
EP1482950A1 (en) 2004-12-08
CN1681514A (zh) 2005-10-12
JP2005528353A (ja) 2005-09-22
WO2003075931A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
WO1997047209A1 (fr) Amelioration du metabolisme lipidique
RU2327463C2 (ru) Лекарственный препарат и пищевой продукт или напиток для улучшения гипергликемического состояния
US20100093780A1 (en) Insulin resistance improving agent
US9642875B2 (en) Compounds and their effects on appetite control and insulin sensitivity
US8236359B2 (en) Use of phytoecdysones in the preparation of a composition for acting on the metabolic syndrome
KR20040104513A (ko) 당뇨병 및 당뇨병의 합병증과 관련된 상태를 포함한당뇨병의 치료방법
US20060148774A1 (en) Hypoglycemic agent
JP2008222656A (ja) 肥満改善および予防用組成物ならびに健康食品
TW201026319A (en) Peptide having anti-diabetic activity and use thereof
KR20080024075A (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
KR101311534B1 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
EP1333838B1 (en) Compounds comprising a phytosterol and/or phytostanol moiety and ascorbic acid and use thereof as weight regulating agents
KR20020089444A (ko) 콜린 염기 및 숙신산을 포함하는 인슐린 저항성 및 당뇨병치료용 상승 조성물
EP1366052B1 (en) Novel multi-ring organic compounds for regulating gut motility and food intake
CN116139127B (zh) 一种酰胺类化合物在制备预防或治疗代谢综合征药物中的用途
KR102717836B1 (ko) 자소엽에서 분리한 화합물을 유효성분으로 포함하는 자가면역질환 예방 및 치료용 조성물
WO2023153533A1 (ko) 후박 추출물을 유효성분으로 함유하는 근육 질환 예방 및 치료용 조성물
WO2014017741A1 (ko) 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물
KR20030004044A (ko) 성장호르몬 분비촉진용 생약추출물
EP1244458A2 (en) Weight promoting composition, method, and product
KR20030004045A (ko) 성장호르몬 분비촉진용 생약추출물
KR20040017891A (ko) 레반을 이용한 비만 개선 식이 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application